| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19,7 M € | +3.3% | 19,1 M € | -1.9% | 19,5 M € | +10.8% | 17,6 M € | +13.1% | 15,5 M € | +1.5% | 15,3 M € | +2.2% | 15,0 M € | -0.1% | 15,0 M € | +9.0% | 13,8 M € | +18.1% | 11,6 M € | -1.9% | 11,9 M € | -3.7% | 12,3 M € | +13.5% | 10,9 M € | +10.4% | 9,8 M € | +3.5% | 9,5 M € | +3.4% | 9,2 M € | -23.8% | 12,1 M € | -59.5% | 29,8 M € | |
| EBITDA | 412,0 k € | -58.2% | 986,0 k € | +160.6% | 378,4 k € | -31.1% | 549,5 k € | +16.2% | 472,9 k € | +3.4% | 457,5 k € | -7.1% | 492,3 k € | +1.4% | 485,5 k € | +41.6% | 343,0 k € | +19.8% | 286,3 k € | +154.2% | -528,4 k € | -394.0% | 179,8 k € | -41.2% | 305,9 k € | +246.7% | 88,2 k € | +119.7% | -447,4 k € | +34.9% | -687,8 k € | -787.0% | 100,1 k € | -98.8% | 8,3 M € | |
| Operating profit | 804,9 k € | +6.0% | 759,4 k € | +106.8% | 367,2 k € | -31.8% | 538,4 k € | +15.6% | 465,7 k € | +2.6% | 453,9 k € | +1.2% | 448,7 k € | -6.9% | 481,9 k € | +43.8% | 335,0 k € | +19.0% | 281,6 k € | +151.4% | -547,7 k € | -416.0% | 173,3 k € | -41.8% | 297,8 k € | +251.4% | 84,7 k € | +118.8% | -451,0 k € | +35.7% | -701,1 k € | -1321.6% | 57,4 k € | -99.3% | 8,3 M € | |
| Profit/loss | 719,9 k € | -11.8% | 816,5 k € | +126.9% | 359,9 k € | -24.3% | 475,6 k € | -1.5% | 482,6 k € | -0.6% | 485,6 k € | +20.3% | 403,6 k € | +7.7% | 374,6 k € | +23.7% | 302,9 k € | -24.3% | 400,3 k € | +167.2% | -595,4 k € | -369.0% | 221,3 k € | +43.9% | 153,8 k € | -92.9% | 2,2 M € | +197.4% | -2,2 M € | -25.1% | -1,8 M € | -241.7% | 1,3 M € | -84.1% | 7,9 M € | |
| Equity | 6,1 M € | +13.3% | 5,4 M € | +17.7% | 4,6 M € | +8.5% | 4,2 M € | +12.6% | 3,8 M € | +14.7% | 3,3 M € | +17.3% | 2,8 M € | +16.8% | 2,4 M € | +18.5% | 2,0 M € | +17.6% | 1,7 M € | +30.3% | 1,3 M € | -31.1% | 1,9 M € | +388.7% | -663,8 k € | +18.8% | -817,7 k € | +93.7% | -12,9 M € | -20.8% | -10,7 M € | -19.9% | -8,9 M € | +12.3% | -10,1 M € | |
| Total assets | 10,5 M € | -1.1% | 10,6 M € | +10.2% | 9,6 M € | -2.9% | 9,9 M € | +7.3% | 9,3 M € | +81.7% | 5,1 M € | -28.0% | 7,1 M € | -2.7% | 7,3 M € | -10.3% | 8,1 M € | -10.9% | 9,1 M € | +24.3% | 7,3 M € | -9.7% | 8,1 M € | +34.6% | 6,0 M € | +21.0% | 5,0 M € | +12.4% | 4,4 M € | +8.7% | 4,1 M € | -17.6% | 4,9 M € | -36.7% | 7,8 M € | |
| Cash | 1,2 M € | +34.9% | 874,3 k € | -7.3% | 942,9 k € | +78.7% | 527,6 k € | -23.4% | 688,8 k € | +129.3% | 300,4 k € | -29.2% | 424,4 k € | -23.4% | 554,3 k € | +35.1% | 410,4 k € | +14.0% | 359,9 k € | +118.1% | 165,0 k € | -36.6% | 260,4 k € | -4.3% | 272,0 k € | -22.7% | 351,8 k € | -17.9% | 428,6 k € | +31.1% | 326,9 k € | +325.0% | 76,9 k € | -88.7% | 679,4 k € | |
| Debts | 4,2 M € | -9.7% | 4,7 M € | -0.2% | 4,7 M € | -11.9% | 5,4 M € | +0.2% | 5,3 M € | +203.1% | 1,8 M € | -58.3% | 4,2 M € | -9.5% | 4,7 M € | -9.7% | 5,2 M € | -22.6% | 6,7 M € | +25.0% | 5,3 M € | -6.4% | 5,7 M € | -14.0% | 6,6 M € | +14.8% | 5,8 M € | -66.5% | 17,2 M € | +19.0% | 14,5 M € | +5.3% | 13,8 M € | -23.3% | 17,9 M € | |
| Staff | 16 | 14,9 | 10,9 | 12,9 | 13 | 11 | 12 | 13 | 12 | 11 | 5,4 | 5,6 | 5 | 5 | 5 | 7,9 | 9,5 | 10,9 | ||||||||||||||||||
Public limited company · Wavre · incorporated on 04/10/2000 · 16,0 ETP
Public limited company profitable and well capitalised. Cash position rising (+34.9%).
Solid counterparty for a standard engagement.
Phibro Animal Health is a Public limited company incorporated in 2000. Its main activity is: Manufacture of pesticides and other agrochemical products. Its registered office is in Wavre. It employs on average 16,0 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette